English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 854068 Online Users : 1450
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
Scope
All of NHRI
癌症研究所
陳立宗
--期刊論文
--圖書
--會議論文/會議摘要
Tips:
please add "double quotation mark" for query phrases to get precise results
please goto advance search for comprehansive author search
Adv. Search
Home
‧
Login
‧
Upload
‧
Help
‧
About
‧
Administer
國家衛生研究院 NHRI
>
癌症研究所
>
陳立宗
>
Browse By Title
Browse By Authors
Browse By Date
Browse By Data Type
Community Detail
Introduction:
NA
Loading...
Collection
期刊論文
[
327
/330]
圖書
[
1
/1]
會議論文/會議摘要
[
115
/179]
Siblings
于重元
[
19
/19]
劉柯俊
[
85
/98]
劉滄梧
[
119
/125]
劉界元(2003-2010)
[
3
/3]
夏和雄(1996-2012)
[
26
/31]
夏興國
[
51
/54]
姜乃榕
[
82
/94]
常慧如
[
39
/44]
張俊彥
[
234
/254]
張光裕
[
69
/79]
張憶壽
[
103
/106]
張文祥
[
52
/53]
張書銘
[
89
/91]
彭汪嘉康(1996-2007)
[
120
/126]
施能耀
[
37
/43]
李家惠
[
29
/29]
李岳倫
[
48
/49]
林素芳
[
32
/32]
楊奕馨
[
41
/42]
江士昇
[
88
/90]
沈哲宏
[
14
/16]
洪文俊
[
88
/88]
莊雙恩
[
82
/91]
蔡坤志
[
32
/34]
蔡慧珍
[
66
/71]
蘇勇曄
[
40
/40]
蘇振良
[
24
/25]
郭靜娟
[
71
/76]
陳尚鴻
[
45
/48]
陳振陽
[
72
/72]
陳美霞(2002-2009)
[
1
/1]
陳詩政
[
2
/2]
陳雅雯
[
38
/39]
黃智興
[
55
/55]
黃道揚
[
26
/26]
丁兆治(2000-2004)
[
5
/5]
其他
[
464
/471]
劉敏(1996-2007)
[
60
/62]
劉玫英(2004-2006)
[
2
/2]
吳成文(1996-2008)
[
53
/55]
曾思文(1997-2007)
[
4
/4]
李冠德(1997-2004)
[
4
/6]
林景太(1999-2007)
[
5
/5]
楊文光(1996-1999)
[
21
/21]
王全正(1996-2003)
[
4
/4]
莊聲宏(1997-2004)
[
11
/11]
詹宗晃(2000-2008)
[
2
/2]
賴基銘(2004-2008)
[
41
/47]
阮麗蓉(2000-2006)
[
6
/7]
陳俊叡(2003-2007)
[
6
/6]
馬彥英(1997-1999)
[
1
/1]
黃奇英(2005-2007)
[
9
/10]
Community Statistics
近3年內發表的文件:74(14.51%)
含全文筆數:443(86.86%)
文件下載次數統計
下載大於0次:443(100.00%)
下載大於100次:424(95.71%)
檔案下載總次數:176904(3.30%)
最後更新時間: 2024-11-28 13:36
Top Upload
Loading...
Top Download
Loading...
Recent Submissions
Pan-Asian adapted ESMO clinical pra...
Nivolumab plus chemotherapy in pati...
Survival of advanced/recurrent gast...
Topiramate suppresses peri-infarct ...
A phase 1 study of biweekly nab-pac...
Plain language summary of the FOENI...
Outcomes of post-immunotherapy dura...
Durvalumab or placebo plus gemcitab...
Impact of previous S-1 treatment on...
Chromatin remodeling-related PRDM1 ...
Jump to a point in the index:
(Choose year)
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1985
1980
1975
1970
1960
1950
(Choose month)
January
February
March
April
May
June
July
August
September
October
November
December
Or type in a year:
Ordering With Most Recent First
Show Oldest First
Showing items 41-50 of 510. (51 Page(s) Totally)
<<
<
1
2
3
4
5
6
7
8
9
10
>
>>
View [
10
|
25
|
50
] records per page
Date
Title
Relation
2022-10
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma
Hepatology International. 2022 Oct;16(5):1137-1149.
2022-10
Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study
Clinical Cancer Research. 2022 Oct 3;28(19):4248-4257.
2022-10
Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression
Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
2022-09-21
Clustering of chromatin remodeling enzymes predicts prognosis and clinical benefit of therapeutic strategy in pancreatic cancer
International Journal of Medical Sciences. 2022 Sep 21;19(10):1615-1627.
2022-09-15
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
American Journal of Cancer Research. 2022 Sep 15;12(9):4267-4278.
2022-09
A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study
European Journal of Cancer. 2022 Sep;173:123-132.
2022-09
Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan
Liver Cancer. 2022 Sep;11(5):426-439.
2022-09
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
Annals of Oncology. 2022 Sep;33(7):S565-S566.
2022-07
Toward collaboration among cancer trials groups in Asia: TCOG perspective
Annals of Oncology. 2022 Jul;33(Suppl. 6):S449.
2022-07
Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience
Annals of Oncology. 2022 Jul;33(Suppl. 6):S535.
Showing items 41-50 of 510. (51 Page(s) Totally)
<<
<
1
2
3
4
5
6
7
8
9
10
>
>>
View [
10
|
25
|
50
] records per page
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
Feedback